About the Company
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
CEO
Exchange
NASDAQ/NGS (GLOBAL SELECT MARKET)
Website
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NK News
Patrick Soon-Shiong's ImmunityBio bags FDA approval for Anktiva to challenge Merck in bladder cancer
ImmunityBio has yet to finalize a registrational trial plan with the FDA in that papillary disease population, Soon-Shiong ...
We don't have any news on NantKwest Inc at the moment.
Loading the latest forecasts...